American Express stock slips again as Trump’s 10% credit-card rate cap keeps AXP in focus
13 January 2026
2 mins read

American Express stock slips again as Trump’s 10% credit-card rate cap keeps AXP in focus

New York, Jan 13, 2026, 12:04 PM EST — Regular session

  • American Express shares dropped further in midday trading, deepening a policy-driven slump among card companies
  • Trump’s plan to cap credit-card interest rates at 10% for one year has stirred up fresh regulatory concerns for lenders
  • Investors now eye two key dates: clarity on enforcement measures and American Express earnings due Jan. 30

Shares of American Express (AXP.N) slipped 0.7% to $356.98 by midday Tuesday, pushing their decline further as Washington once again scrutinizes the credit-card sector.

The pressure comes after President Donald Trump proposed a one-year limit on credit-card interest rates at 10%, far below the usual rates in the U.S. Investors are scrambling to figure out how such a cap would impact interest income, along with the associated rewards and fees.

AmEx dropped 3.8% on Monday after Trump said the cap would kick in on Jan. 20, dragging Visa (V.N) and Mastercard (MA.N) down roughly 2%. UBS Global analysts noted, “It would take an Act of Congress for such rate caps to be in place,” while Seaport Research’s Bill Ryan linked Trump’s renewed push to voter concerns about affordability. (Reuters)

JPMorgan Chase CFO Jeremy Barnum slammed the proposal as “very bad for consumers, very bad for the economy,” warning it would force banks to slash credit availability. CEO Jamie Dimon added the hit to co-branded cards “would be dramatic.” Overnight, Trump threw his weight behind cutting card swipe fees—the charges merchants pay to process payments—shifting the debate from lending rates to the payments infrastructure. The Federal Reserve put average credit card rates at 20.97% in November. The Electronic Payments Coalition noted that under a 10% cap, most accounts linked to credit scores below 740 would either be shut down or heavily restricted. (Reuters)

American Express operates a closed-loop network and issues its own cards, making it vulnerable to both lending economics and transaction fees. While many of its products cater to high-spending customers, it also generates interest income from revolving balances—debt that customers carry month to month.

The missing piece is mechanics. Trump hasn’t explained how lenders would be forced to comply, and that uncertainty has kept the stock moving on headlines instead of fundamentals.

The downside is clear: if the cap gains momentum, issuers might tighten underwriting, shut accounts, and hike prices—actions that would hit card spending and squeeze fee income. On top of that, a tough battle over swipe fees would create another strain, particularly for companies dependent on network revenue.

The debate arrives just as earnings season kicks off, with investors scouring for early signs of credit strain and shifts in reward strategies. For AmEx, keep an eye on comments about spending patterns and delinquencies — that is, late payments — amid the changing policy climate.

American Express plans to release its fourth-quarter results on Jan. 30 at 8:30 a.m. ET. Investors will also keep an eye on Jan. 20, the date Trump mentioned, for any move that might push the proposal into draft legislation or an enforceable rule. (Americanexpress)

Stock Market Today

  • ABBV inks drug pricing deal with Trump, joins PD-1xVEGF bandwagon
    January 13, 2026, 2:32 PM EST. AbbVie said it signed a U.S. pricing agreement with the Trump administration to cut list prices to match those in comparable developed markets, backing the MFN proposal. The deal includes a three-year exemption from import tariffs on pharmaceutical ingredients if AbbVie expands U.S. manufacturing, and a pledge to invest $100 billion over the next decade in domestic R&D and capital. The government says 16 of 17 large drugmakers have reached similar accords; Regeneron remains in talks. In a separate release, AbbVie agreed to an exclusive license with RemeGen for its PD-1xVEGF bispecific, RC148. AbbVie will pay an upfront $650 million and up to $4.95 billion in milestones, plus royalties, for rights outside Greater China. RC148 is in phase II in China, with potential in NSCLC and CRC. Competitors include Summit, BioNTech/Bristol Myers, Merck and Pfizer pursuing PD-1/VEGF programs.
POSCO Holdings stock jumps 12% after $700 million bond sale — what investors watch next
Previous Story

POSCO Holdings stock jumps 12% after $700 million bond sale — what investors watch next

UnitedHealth stock slides after Senate report targets Medicare Advantage coding as UNH earnings loom
Next Story

UnitedHealth stock slides after Senate report targets Medicare Advantage coding as UNH earnings loom

Go toTop